Search the Newsreel

BCP Investment Corporation Announces Second Quarter 2026 Financial Results

Declares Monthly Base Distributions of $0.09 Per Share for October, November and December 2026 Amends KeyBank Credit Facility Subsequent to Quarter End, Increasing Committed Capacity to $150 Million, Reducing Reinvestment Period Spread by 30 Basis Points and Extending Maturity to 2031; Repays and Terminates …

SBC Medical Group (SBC) to Release Quarterly Earnings on Thursday

SBC Medical Group (NASDAQ:SBC) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts forecasting earnings of $0.12 per share and revenue of $45.3710 million. The company previously surpassed expectations in Q1 2026, reporting $0.11 EPS against …

BCP Investment Corp Q2 2026: Revenue $15.17M, EPS $(0.80) — 10-Q Summary

BCE Inc (BCE) (Q2 2026) Earnings Call Highlights: AI Fabric Momentum and Fiber Growth Drive ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Consolidated revenue increased 1.5% and adjusted EBITDA grew 1%, with over $1 billion in free …

BCE Inc (BCE) (Q2 2026) Earnings Call Highlights: AI Fabric Momentum and Fiber Growth Drive ... By GuruFocus

BCE Inc. reported Q2 2026 earnings with positive points including increased revenue, improved postpaid wireless churn, and strong fiber growth. The company also highlighted significant momentum in its Bell AI Fabric, with 335 MW contracted capacity and construction on track for new facilities. Despite …

Why Are Zevia (NYSE:ZVIA) Shares Lower After Revenue Beat?

AbCellera Biologics Inc. Stock 12‑Month Price Target Raised to $10.75, Implies 82% Upside

AbCellera Biologics Inc. (ABCL) has seen its average 12-month price target raised to $10.75 by 8 analysts, up from $10.50, with individual forecasts ranging from $7 to $13. This updated target suggests an 82% potential upside based on the August 5th closing price. The …

HSBC cancels 446,000 shares in latest Hong Kong buy-back

HSBC Holdings has repurchased and cancelled 446,000 of its Hong Kong-listed ordinary shares, valued at approximately US$9 million, as part of a buy-back program announced on August 5, 2026. This action aims to manage the bank's capital structure and return surplus capital to shareholders. …

BCE (BCE) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, BCE (BCE) reported revenue of $4.46 billion, up 1.5% over the same period last year. EPS came in at $0.47, compared to $0.46 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $4.4 …

TBC Bank Group Q2 Earnings Call Highlights

Key Points Interested in TBC Bank Group PLC? Here are five stocks we like better. TBC Bank Group delivered strong second-quarter results: Net profit rose 12% year over year to GEL 386 million, with a 23.6% return on equity. Operating income increased 10%, net …

Does Brunswick’s EPS Jump And Buybacks Shift The Bull Case For BC?

BCE (BCE) Q2 Earnings and Revenues Top Estimates

BCE (BCE) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

BCE Inc Backs 2026 Adj EPS View of Down 5%-11% >BCE.T

BCE Inc. has reaffirmed its adjusted earnings per share (EPS) outlook for 2026, anticipating a decline of 5% to 11%. This statement reflects the company's financial projections and market expectations for its future performance.

Up 58% in 12 Months, This Is Where Rocket Lab Will End The Year

Quick Read RKLB earns a BUY with an $82 year-end target, backed by 63% revenue growth and a record $2.2 billion backlog. ASTS posts just $15M in quarterly revenue on a $17.5B market cap, while Planet Labs carries roughly one-fifth of RKLB's $41B valuation. …

Earnings call transcript: AbCellera misses Q2 2026 estimates as revenue drops

AbCellera Biologics Inc. reported a wider-than-expected Q2 2026 loss and revenue significantly below analyst estimates, with revenue dropping by 76% year-over-year. The company attributed the revenue decline to a strategic shift from external collaborations to internal drug development, leading to increased R&D spending. Despite …

Earnings Flash (BCE.TO) BCE Inc. Posts Q2 Adjusted EPS C$0.65 vs. FactSet Est of C$0.64

BCE Inc. (BCE.TO) reported its Q2 adjusted Earnings Per Share (EPS) of C$0.65, surpassing FactSet's estimate of C$0.64. The company also saw an increase in Q2 adjusted earnings and operating revenue, reaffirming its 2026 guidance and maintaining a higher capital expenditure plan for the …

AbCellera Biologics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABCL) 2026-08-06

This document is AbCellera Biologics' 10-Q filing for its Q2 2026 earnings report. A 10-Q is a comprehensive quarterly report filed by public companies with the SEC, containing unaudited financial performance. It provides a detailed overview of the company's financial condition and results of …

HSBC HOLDINGS PLC ANNOUNCES INCREASE OF (A) THE MAXIMUM TENDER AMOUNT OF ITS TENDER OFFERS FOR FOUR SERIES OF NOTES AND (B) THE MAY 2028 NOTES SUB-CAP IN RESPECT OF THE MAY 2028 NOTES

LONDON, Aug. 6, 2026 /PRNewswire/ -- HSBC Holdings plc (the 'Company', 'we' or 'us') announces the increase of the maximum tender amount for its offers to purchase for cash the outstanding series of notes listed in the table below, previously announced on August 5, …

KBC Group NV erhöht Ergebnisprognose für das Jahr 2026

J.P. Morgan Maintains Brunswick Corp(BC.US) With Hold Rating, Cuts Target Price to $80

J.P. Morgan has reiterated its Hold rating for Brunswick Corp (BC.US) but has lowered its price target to $80. This adjustment reflects the firm's updated valuation for the company.

Results: RBC Bearings Incorporated Exceeded Expectations And The Consensus Has Updated Its Estimates

RBC Bearings Incorporated (NYSE:RBC) recently reported strong quarterly results, with revenues surpassing expectations by 2.0% and statutory earnings per share exceeding forecasts by 13%. Despite the positive performance, analysts have largely maintained their future estimates and price targets, indicating no major shift in their …

Once Upon a Farm Q2 2026 Earnings: 42% Sales Growth Comes With Margin Pressure

BCP Investment Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BCP Investment: Q2 Earnings Snapshot

Zevia PBC (ZVIA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Zevia PBC 2026 Q2 - Results - Earnings Call Presentation (NYSE:ZVIA) 2026-08-06

Key Points Interested in Zevia PBC? Here are five stocks we like better. Q2 sales increased 1.1% to $45 million, while adjusted EBITDA improved to approximately $0.5 million from $0.2 million a year earlier. Gross margin edged up to 48.9%, although higher aluminum costs …

Once Upon A Farm (OFRM) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Once Upon a Farm Raises 2026 Sales Outlook to $327M-$335M

Stifel Nicolaus Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbCellera Biologics Inc (NASDAQ:ABCL) completed enrollment for the phase 2 study of ABCL-635 in treating …

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items. This …

Is AbCellera Biologics Inc (ABCL) Facing Headwinds After Q2 Earnings Miss? GF Score: 59/100

AbCellera Biologics Inc (ABCL) reported a significant Q2 2026 earnings miss with revenues of $4.1 million against an estimated $7.78 million and a net loss of $55.4 million. Despite the financial shortfall, the company maintains a strong liquidity position of over $565 million in …

Zevia PBC Q2 2026: Net sales $45.0M; Adjusted EBITDA $0.5M; Net loss $2.9M

Zevia PBC reported Q2 2026 net sales of $45.0 million, a 1.1% increase year-over-year, with an improved gross profit margin of 48.9%. The company posted a GAAP net loss of $2.9 million and Adjusted EBITDA of $0.5 million. Zevia PBC maintained a strong cash …

Abcellera Biologics earnings missed, revenue fell short of estimates

BCE in a RRIF, gold ETFs, geographic asset allocation, and more of your questions

Gordon Pape addresses readers' financial questions, discussing the suitability of BCE Inc. in an RRIF account, recommending geographic asset allocation for equity portfolios, and analyzing the CI Gold+ Giants Covered Call ETF. He also provides insights on preferred shares as an income option for …

Royal Bank of Canada Decreases Stock Holdings in RBC Bearings Incorporated $RBC

Royal Bank of Canada reduced its stake in RBC Bearings Incorporated by 13.7% in the first quarter, selling 7,599 shares but still holding 47,691 shares valued at $25.9 million. Despite this reduction, analyst sentiment for RBC Bearings remains largely positive, with a "Moderate Buy" …